QDEL:NSD-Quidel Corporation (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 40.02

Change

-1.12 (-2.72)%

Market Cap

USD 2.62B

Volume

0.62M

Analyst Target

USD 264.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-1.81 (-2.43%)

USD 27.48B
PODD Insulet Corporation

-6.04 (-2.20%)

USD 16.52B
BRKR Bruker Corporation

-0.10 (-0.18%)

USD 8.98B
MASI Masimo Corporation

+0.83 (+0.52%)

USD 7.71B
PRCT Procept Biorobotics Corp

-3.30 (-3.45%)

USD 4.99B
AXNX Axonics Modulation Technologie..

-0.04 (-0.06%)

USD 3.60B
TMDX TransMedics Group Inc

+1.32 (+1.44%)

USD 2.89B
NARI Inari Medical Inc

-0.53 (-1.03%)

USD 2.85B
LIVN LivaNova PLC

+0.58 (+1.09%)

USD 2.80B
UFPT UFP Technologies Inc

-28.76 (-8.37%)

USD 2.65B

ETFs Containing QDEL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.70% 36% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.70% 36% F 19% F
Trailing 12 Months  
Capital Gain -36.95% 34% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.95% 34% F 20% F
Trailing 5 Years  
Capital Gain -37.65% 62% D 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.65% 62% D 28% F
Average Annual (5 Year Horizon)  
Capital Gain -11.97% 25% F 19% F
Dividend Return -11.97% 25% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 58.33% 57% F 33% F
Risk Adjusted Return -20.53% 31% F 24% F
Market Capitalization 2.62B 91% A- 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.